Grünenthal Press Releases 2014

US Patient Ambassador – Susan Stephenson

Susan Stephenson - US Patient Ambassador

We are pleased to welcome Susan Stephenson as the newly designated US Patient Ambassador for Grünenthal.

Susan Stephenson, a former nurse, has Ehlers-Danlos Syndrome (EDS), a genetic connective tissue disorder. She contributes her time and skills to several health and human service non-profit organizations. She helped establish the Ehlers Danlos National Foundation, serving as one of their board members and volunteering time with the organization by creating awareness and support for EDS. She was instrumental in organizing the first EDS conference in 1988 which today is an annual event attracting international attendees.

She also volunteers her time with various non-profit organizations including the Richmond, Virginia “Giving Heart” organization. Through her work with the Giving Heart organization, Susan has helped prepare over 3,000 Thanksgiving dinners annually to the local community.

Susan serves as a member of the Grünenthal USA Pain Day Advisory board. Her work on the board helps shape the annual meeting and networking event as well as the creation of the “Unsung Hero Award.”

We are honored to have Susan as our US Patient Ambassador. Her enduring passion and contributions drive the awareness of those living with pain.

About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grünenthal′s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved preliminary revenues of € 973 mn.

More information: